Literature DB >> 20483790

Mycobacterium tuberculosis upregulates microglial matrix metalloproteinase-1 and -3 expression and secretion via NF-kappaB- and Activator Protein-1-dependent monocyte networks.

Justin A Green1, Paul T Elkington, Caroline J Pennington, Federico Roncaroli, Shruti Dholakia, Rachel C Moores, Anwen Bullen, Joanna C Porter, Dan Agranoff, Dylan R Edwards, Jon S Friedland.   

Abstract

Inflammatory tissue destruction is central to pathology in CNS tuberculosis (TB). We hypothesized that microglial-derived matrix metalloproteinases (MMPs) have a key role in driving such damage. Analysis of all of the MMPs demonstrated that conditioned medium from Mycobacterium tuberculosis-infected human monocytes (CoMTb) stimulated greater MMP-1, -3, and -9 gene expression in human microglial cells than direct infection. In patients with CNS TB, MMP-1/-3 immunoreactivity was demonstrated in the center of brain granulomas. Concurrently, CoMTb decreased expression of the inhibitors, tissue inhibitor of metalloproteinase-2, -3, and -4. MMP-1/-3 secretion was significantly inhibited by dexamethasone, which reduces mortality in CNS TB. Surface-enhanced laser desorption ionization time-of-flight analysis of CoMTb showed that TNF-alpha and IL-1beta are necessary but not sufficient for upregulating MMP-1 secretion and act synergistically to drive MMP-3 secretion. Chemical inhibition and promoter-reporter analyses showed that NF-kappaB and AP-1 c-Jun/FosB heterodimers regulate CoMTb-induced MMP-1/-3 secretion. Furthermore, NF-kappaB p65 and AP-1 c-Jun subunits were upregulated in biopsy granulomas from patients with cerebral TB. In summary, functionally unopposed, network-dependent microglial MMP-1/-3 gene expression and secretion regulated by NF-kappaB and AP-1 subunits were demonstrated in vitro and, for the first time, in CNS TB patients. Dexamethasone suppression of MMP-1/-3 gene expression provides a novel mechanism explaining the benefit of steroid therapy in these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483790     DOI: 10.4049/jimmunol.0903811

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Matrix metalloproteinase proteolysis of the mycobacterial HSP65 protein as a potential source of immunogenic peptides in human tuberculosis.

Authors:  Sergey A Shiryaev; Piotr Cieplak; Alexander E Aleshin; Qing Sun; Wenhong Zhu; Khatereh Motamedchaboki; Alexander Sloutsky; Alex Y Strongin
Journal:  FEBS J       Date:  2011-08-08       Impact factor: 5.542

2.  The involvement of NADPH oxidase-mediated ROS in cytokine secretion from macrophages induced by Mycobacterium tuberculosis ESAT-6.

Authors:  Weiwei Liu; Yuan Peng; Yanlin Yin; Zhihui Zhou; Wanding Zhou; Yalei Dai
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

3.  Macrophage-Microglia Networks Drive M1 Microglia Polarization After Mycobacterium Infection.

Authors:  Yongwei Qin; Xiaolei Sun; Xiaoyi Shao; Chun Cheng; Jinrong Feng; Wei Sun; Delin Gu; Wei Liu; Feifan Xu; Yinong Duan
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

4.  Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.

Authors:  Selvakumar Subbian; Liana Tsenova; Paul O'Brien; Guibin Yang; Mi-Sun Koo; Blas Peixoto; Dorothy Fallows; Jerome B Zeldis; George Muller; Gilla Kaplan
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

Review 5.  Protection versus pathology in tuberculosis: recent insights.

Authors:  Andrea M Cooper; Egidio Torrado
Journal:  Curr Opin Immunol       Date:  2012-05-19       Impact factor: 7.486

6.  Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.

Authors:  Catherine W M Ong; Paul T Elkington; Jon S Friedland
Journal:  Am J Respir Crit Care Med       Date:  2014-07-01       Impact factor: 21.405

7.  Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1/2.

Authors:  Chien-Min Chen; Yi-Hsien Hsieh; Jin-Ming Hwang; Hsun-Jin Jan; Shu-Ching Hsieh; Shin-Huey Lin; Chung-Yu Lai
Journal:  Tumour Biol       Date:  2014-12-20

Review 8.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222

9.  Heme Oxygenase-1 Regulation of Matrix Metalloproteinase-1 Expression Underlies Distinct Disease Profiles in Tuberculosis.

Authors:  Bruno B Andrade; Nathella Pavan Kumar; Eduardo P Amaral; Nicolas Riteau; Katrin D Mayer-Barber; Kevin W Tosh; Nolan Maier; Elisabete L Conceição; Andre Kubler; Rathinam Sridhar; Vaithilingam V Banurekha; Mohideen S Jawahar; Theolis Barbosa; Vincent C Manganiello; Joel Moss; Joseph R Fontana; Beatriz E Marciano; Elizabeth P Sampaio; Kenneth N Olivier; Steven M Holland; Sharon H Jackson; Mahtab Moayeri; Stephen Leppla; Irini Sereti; Daniel L Barber; Thomas B Nutman; Subash Babu; Alan Sher
Journal:  J Immunol       Date:  2015-08-12       Impact factor: 5.422

10.  Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.

Authors:  Naomi F Walker; Simon O Clark; Tolu Oni; Nuria Andreu; Liku Tezera; Shivani Singh; Luísa Saraiva; Bernadette Pedersen; Dominic L Kelly; Julia A Tree; Jeanine M D'Armiento; Graeme Meintjes; Francesco A Mauri; Ann Williams; Robert J Wilkinson; Jon S Friedland; Paul T Elkington
Journal:  Am J Respir Crit Care Med       Date:  2012-02-16       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.